ThermiGen owner Almirall said today that it sold its ThermiGen assets to Celling Biosciences for an undisclosed amount.
The deal is expected to close on March 29, Barcelona-based Almirall said. Through the deal, Austin, Texas-based Celling Biosciences will take control of Thermi and its 94 Dallas-based employees as well as its more than 2,000 users, the companies said.
“Almirall continues to refocus its business towards medical dermatology. With this divestment, Almirall completes its strategic realignment and puts Thermi business in very good hands to capture the potential of the new Arvati innovative platform,” Almirall CEO Peter Guenter said in a press release.
Last year, Thermi reported $18 million in net sales, Almirall said.
“We are excited about the acquisition announced today and the expansion of our portfolio with ThermiGen’s leading energy-based technology. Acquiring this technology will allow Celling to combine their unique cellular therapy devices with the existing ThermiGen technology to offer physicians a unique scientific approach to treat their patience,” Celling Biosciences CEO Kevin Dunworth said in a prepared statement.
Almirall originally acquired ThermiGen in February 2016 for approximately $82 million.
Last September, Almirall announced it picked up Allergan’s US medical dermatology portfolio for approximately $550 million. In December, the company announced an approximately $280 million (EU €250 million) offering to help pay for the acquisition.
